T he treatment of patients with infrapopliteal disease has become common in our clinical practice as the number of patients with symptomatic peripheral arterial disease skyrockets, affecting 12% to 29% of the elderly and as many as 8 to 10 million Americans (1, 2) . Contemporary data suggest that >10% of these patients have critical limb ischemia (CLI), defined as rest pain, nonhealing wounds, or gangrene (3). Historically, treatments for CLI have yielded poor results. At 1 year, 25% of patients will be dead, 30% will have undergone amputation, and only 45% will remain alive with both limbs (4, 5) . Given the high comor- Medical Group, Englewood, Colorado. Dr. Tsai has reported that he has no relationships relevant to the contents of this paper to disclose. 
